MarketBeat’s Chris Marott argues that three sub-$5 names have unusually strong upside because they combine analyst coverage, price-target gaps, and in two cases real operating progress: Grab, Vaxart, and ThredUp. The video is essentially a stock-pick rundown with different risk profiles: Grab as a profitable, Southeast Asia super-app with analyst support; Vaxart as a speculative biotech tied to oral vaccines and FDA milestones; and ThredUp as a beaten-down resale platform with earnings ahead and a big consensus target gap.
Watch on YouTube ›Get the market thesis, key claims, assets, contradictions, and follow-up questions from any financial video — then unlock a version personalized to your portfolio, watchlist, and favorite speakers.
This is a MarketBeat stock-picking segment built around three “penny stocks” defined here as names under $5, not necessarily under $1. Chris Marott’s core premise is that the market has pushed these names down too far relative to analyst expectations, and that each one has a distinct story that could drive upside. The host frames them as “early buy or buy the dip opportunities,” and Marott says he screened for volatile market conditions, under-$5 pricing, positive analyst sentiment, and consensus price targets above current prices. The first name is Grab Holdings (GRAB). Marott describes it as an “ecommerce meets technology meets everything else” business and “an everything app of Southeast Asia.” He emphasizes that Grab just became profitable for the first time and that analysts project roughly 54% upside. …
Near term, this is a risk-on/risk-off trade: if small caps stabilize, the large price-target gaps could matter; if volatility stays high, these names can keep bleeding despite positive stories. ThredUp’s earnings and Vaxart’s trial headlines are the most immediate catalysts.
Over the next few months, the better-looking names are the ones with visible operating traction—Grab first, then ThredUp if revenue beats continue—while Vaxart remains a binary catalyst story. The setup improves only if the market stops penalizing small caps and company results keep confirming the bull cases.
Structurally, the transcript is pointing to three durable themes: Southeast Asia platform scale, consumer resale growth, and optionality in oral vaccine delivery. The long-term implication is that some sub-$5 stocks are not distressed junk; they can be early-stage or mispriced businesses with real category exposure.
Grab Holdings is a profitable, revenue-growing Southeast Asia super-app with about 54% upside to analyst targets.
The speaker says Grab just turned profitable, is growing revenue year over year and sequentially, and analysts see substantial upside from current levels.
Vaxart could rise roughly 195% if its oral vaccine pipeline advances through FDA approval.
The speaker ties the upside to several clinical-stage oral vaccine candidates, arguing that successful approval would unlock a market category that is not yet widely served.
Thread Up's stock decline may reflect a market bet that easing rates would shift consumers away from secondhand shopping, but the company still has meaningful upside if earnings confirm revenue growth and a path to profitability.
The speaker connects the selloff to macro expectations around consumer spending, then points to recent revenue beats and the upcoming earnings report as the main test of the thesis.
How did you select the three stocks for this list?
Chris says he screened for stocks under $5 with very positive analyst sentiment. He chose names with consensus targets above current prices and interesting stories, noting that a couple would be familiar to channel viewers while one would be new.
Why is Grab Holdings down right now despite its diversification?
Chris attributes the weakness mainly to broad market volatility and the fact that small-cap penny stocks are often avoided in a flight to quality. He also notes that analysts still cover it well and see meaningful upside.
Is Grab actually generating revenue, and is that revenue growing?
Yes. Chris says Grab is generating revenue that is growing both year over year and sequentially. He adds that the company recently turned profitable on an adjusted EPS basis and may also have been profitable on a GAAP basis, though smaller.
Unlock the full claims, asset map, scores, related transcripts, follow-up questions, and AI chat — shaped around your portfolio, watchlist, favorite speakers, and risks.
